Left Ventricular Function and Response to Enalapril in Patients With Duchenne Muscular Dystrophy During the Second Decade of Life

Claudio Ramaciotti, Lisa C. Heistein, Melanie Coursey, Matthew S. Lemler, Reenu S. Eapen, Susan T. Iannaccone, William A. Scott

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The role of angiotensin-converting enzyme inhibitors in the management of cardiomyopathy related to Duchenne muscular dystrophy has not been completely defined. The purposes of this study were to describe the response to enalapril and its relation to dystrophin mutation type, ventricular size, or age at the onset of left ventricular (LV) systolic dysfunction. Serial clinical and echocardiographic data from 50 patients with Duchenne muscular dystrophy (aged 10 to 20 years) were retrospectively reviewed. Twenty-seven patients (46%) developed LV systolic dysfunction (mean age 13.2 ± 2.4 years). Ten (43%) responded to enalapril with the normalization of function. Responders and nonresponders developed LV systolic dysfunction at similar ages (p = 0.91). At the onset of LV systolic dysfunction, only 2 patients (1 responder, 1 nonresponder) had dilated left ventricles. The positive response to enalapril was sustained in 7 patients (median follow-up 23 months, range 5 to 58). No specific mutation was associated with the response to enalapril (p = 0.66) or predictive of the development of LV systolic dysfunction (p = 0.8). In conclusion, 10 of 26 patients (43%) with Duchenne muscular dystrophy responded to the use of enalapril with normalization of the shortening fraction. Age at the onset of LV systolic dysfunction and the type of mutation were not predictors of response to enalapril.

Original languageEnglish (US)
Pages (from-to)825-827
Number of pages3
JournalAmerican Journal of Cardiology
Volume98
Issue number6
DOIs
StatePublished - Sep 8 2006

Fingerprint

Enalapril
Duchenne Muscular Dystrophy
Left Ventricular Dysfunction
Left Ventricular Function
Age of Onset
Mutation
Dystrophin
Cardiomyopathies
Angiotensin-Converting Enzyme Inhibitors
Heart Ventricles

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{578ce52d1b104043a509796dbeb34f21,
title = "Left Ventricular Function and Response to Enalapril in Patients With Duchenne Muscular Dystrophy During the Second Decade of Life",
abstract = "The role of angiotensin-converting enzyme inhibitors in the management of cardiomyopathy related to Duchenne muscular dystrophy has not been completely defined. The purposes of this study were to describe the response to enalapril and its relation to dystrophin mutation type, ventricular size, or age at the onset of left ventricular (LV) systolic dysfunction. Serial clinical and echocardiographic data from 50 patients with Duchenne muscular dystrophy (aged 10 to 20 years) were retrospectively reviewed. Twenty-seven patients (46{\%}) developed LV systolic dysfunction (mean age 13.2 ± 2.4 years). Ten (43{\%}) responded to enalapril with the normalization of function. Responders and nonresponders developed LV systolic dysfunction at similar ages (p = 0.91). At the onset of LV systolic dysfunction, only 2 patients (1 responder, 1 nonresponder) had dilated left ventricles. The positive response to enalapril was sustained in 7 patients (median follow-up 23 months, range 5 to 58). No specific mutation was associated with the response to enalapril (p = 0.66) or predictive of the development of LV systolic dysfunction (p = 0.8). In conclusion, 10 of 26 patients (43{\%}) with Duchenne muscular dystrophy responded to the use of enalapril with normalization of the shortening fraction. Age at the onset of LV systolic dysfunction and the type of mutation were not predictors of response to enalapril.",
author = "Claudio Ramaciotti and Heistein, {Lisa C.} and Melanie Coursey and Lemler, {Matthew S.} and Eapen, {Reenu S.} and Iannaccone, {Susan T.} and Scott, {William A.}",
year = "2006",
month = "9",
day = "8",
doi = "10.1016/j.amjcard.2006.04.020",
language = "English (US)",
volume = "98",
pages = "825--827",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Left Ventricular Function and Response to Enalapril in Patients With Duchenne Muscular Dystrophy During the Second Decade of Life

AU - Ramaciotti, Claudio

AU - Heistein, Lisa C.

AU - Coursey, Melanie

AU - Lemler, Matthew S.

AU - Eapen, Reenu S.

AU - Iannaccone, Susan T.

AU - Scott, William A.

PY - 2006/9/8

Y1 - 2006/9/8

N2 - The role of angiotensin-converting enzyme inhibitors in the management of cardiomyopathy related to Duchenne muscular dystrophy has not been completely defined. The purposes of this study were to describe the response to enalapril and its relation to dystrophin mutation type, ventricular size, or age at the onset of left ventricular (LV) systolic dysfunction. Serial clinical and echocardiographic data from 50 patients with Duchenne muscular dystrophy (aged 10 to 20 years) were retrospectively reviewed. Twenty-seven patients (46%) developed LV systolic dysfunction (mean age 13.2 ± 2.4 years). Ten (43%) responded to enalapril with the normalization of function. Responders and nonresponders developed LV systolic dysfunction at similar ages (p = 0.91). At the onset of LV systolic dysfunction, only 2 patients (1 responder, 1 nonresponder) had dilated left ventricles. The positive response to enalapril was sustained in 7 patients (median follow-up 23 months, range 5 to 58). No specific mutation was associated with the response to enalapril (p = 0.66) or predictive of the development of LV systolic dysfunction (p = 0.8). In conclusion, 10 of 26 patients (43%) with Duchenne muscular dystrophy responded to the use of enalapril with normalization of the shortening fraction. Age at the onset of LV systolic dysfunction and the type of mutation were not predictors of response to enalapril.

AB - The role of angiotensin-converting enzyme inhibitors in the management of cardiomyopathy related to Duchenne muscular dystrophy has not been completely defined. The purposes of this study were to describe the response to enalapril and its relation to dystrophin mutation type, ventricular size, or age at the onset of left ventricular (LV) systolic dysfunction. Serial clinical and echocardiographic data from 50 patients with Duchenne muscular dystrophy (aged 10 to 20 years) were retrospectively reviewed. Twenty-seven patients (46%) developed LV systolic dysfunction (mean age 13.2 ± 2.4 years). Ten (43%) responded to enalapril with the normalization of function. Responders and nonresponders developed LV systolic dysfunction at similar ages (p = 0.91). At the onset of LV systolic dysfunction, only 2 patients (1 responder, 1 nonresponder) had dilated left ventricles. The positive response to enalapril was sustained in 7 patients (median follow-up 23 months, range 5 to 58). No specific mutation was associated with the response to enalapril (p = 0.66) or predictive of the development of LV systolic dysfunction (p = 0.8). In conclusion, 10 of 26 patients (43%) with Duchenne muscular dystrophy responded to the use of enalapril with normalization of the shortening fraction. Age at the onset of LV systolic dysfunction and the type of mutation were not predictors of response to enalapril.

UR - http://www.scopus.com/inward/record.url?scp=33748062315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748062315&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2006.04.020

DO - 10.1016/j.amjcard.2006.04.020

M3 - Article

C2 - 16950195

AN - SCOPUS:33748062315

VL - 98

SP - 825

EP - 827

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -